Alchemab Therapeutics
To add a bio or update company history, please click update information.
News from Alchemab Therapeutics
Alchemab Therapeutics
9 Jul 2026
Alchemab Therapeutics secures £25m Series A extension from British Business Bank to scale antibody drug discovery pipeline for hard-to-treat diseases
Alchemab Therapeutics is a clinical-stage biotechnology company that uncovers protective antibodies from disease-resilient individuals to discover and develop novel therapeutics. Its Resiliome platform combines a large human antibody database with AI-derived algorithms and lab validation to identify antibodies that protect against hard-to-treat diseases.
Alchemab Therapeutics
9 Sept 2025
Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform
Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.
Alchemab Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £49m
- alchemab.com
- Update Information
More venture news
- 5 Aug 2026
MironidMironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Series BLife Sciences - 29 Jul 2026
QureightQureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences - 7 Jul 2026
Healome TherapeuticsHealome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences